Seeking Alpha
18 Aug 2026, 11:30 UTC · 2h ago
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
18 Aug 2026, 11:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Milestone Pharmaceuticals' equity has fallen to $18M while liabilities have doubled to $163M. — Extreme leverage and shrinking equity significantly increase the risk of insolvency or highly dilutive financing.
-0.90Q2 revenue was only $559K despite over 1,200 prescriptions, indicating heavy discounting and poor payer coverage. — Low revenue-per-script suggests the product lacks pricing power and is struggling to secure insurance reimbursement.
-0.70The company reported a $39M cash burn for the first half of the year against $170M in cash. — While cash is available, the burn rate combined with rising debt limits the operational runway.
-0.50Continue reading
6 related stories
Search tags
CARDAMYST has captured only approximately 20% of the PSVT market due to weak differentiation from low-cost generics. — Lack of competitive advantage against cheaper alternatives caps the total addressable market and growth potential.
Which stocks this story touches
The company faces weak product differentiation, poor commercial uptake, deteriorating financial health, and a 'Sell' rating.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
7h ago
